低肿瘤负荷前列腺癌患者中SUV可充分量化18F-DCFPyL病灶摄取
该回顾性研究纳入116例接受18F-DCFPyL PET/CT的前列腺癌患者,共勾勒436个病灶,评估SUVpeak与肿瘤-血池比(TBR)的相关性。在总肿瘤体积小于200 cm3的患者中,SUVpeak与TBR高度相关(R2=0.931),且不受疾病分期、PSA水平或肿瘤体积影响,SUVpeak对示踪剂摄取时间的依赖小于TBR。结论认为SUVpeak可作为低体积前列腺癌患者18F-DCFPyL PET的简化半定量指标。
要点
- 低肿瘤负荷(<200 cm3)前列腺癌患者中,SUVpeak与TBR高度相关(R2=0.931)。
- SUVpeak与TBR的相关性不受疾病分期、PSA水平或肿瘤体积影响。
- SUVpeak对示踪剂摄取时间的依赖小于TBR,更便于临床推广应用。
核心结论
- 对于18F-DCFPyL PET/CT,SUVpeak与TBR高度相关,是低体积前列腺癌(<200 cm3)患者有价值的简化半定量指标。
- SUVpeak可作为影像生物标志物用于肿瘤特征描述和治疗效果监测。
研究设计与样本
- 回顾性纳入116例接受18F-DCFPyL PET/CT显像的前列腺癌患者,共半自动勾勒436个怀疑前列腺癌的摄取病灶。
- 将每位患者最浓聚病灶的SUVpeak与TBR进行线性回归分析,并按初诊分期、生化复发再分期和转移性去势抵抗性前列腺癌分层评估相关性。
- 同时评估相关性随示踪剂摄取时间、前列腺特异性抗原水平和PET阳性肿瘤体积的变化。
主要发现
- 共勾勒436个病灶,每位患者中位病灶数为1(范围1-66)。
- 在总肿瘤体积小于200 cm3的前列腺癌患者中,SUVpeak与TBR相关性良好(R2=0.931)。
- SUV与TBR的相关性不受疾病分期、前列腺特异性抗原水平或肿瘤体积影响。
- SUVpeak对示踪剂摄取时间的依赖小于TBR。
临床怎么用
- 在低肿瘤负荷(总肿瘤体积<200 cm3)前列腺癌患者中,可采用SUVpeak作为18F-DCFPyL PET/CT的简化半定量指标替代TBR。
- SUVpeak可用于肿瘤特征描述和治疗效果监测的影像生物标志物。
局限性
- 本研究为回顾性设计。
- SUVpeak与TBR的高度相关性仅在总肿瘤体积小于200 cm3的患者中报告(R2=0.931)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In prostate cancer (PCa) patients, the tumor-to-blood ratio (TBR) has been validated as the preferred simplified method for lesional 18F-DCFPyL (a radiolabeled prostate-specific membrane antigen ligand) uptake quantification on PET. In contrast to SUVs, the TBR accounts for variability in arterial input functions caused by differences in total tumor burden between patients (the sink effect). However, TBR depends strongly on tracer uptake interval and has worse repeatability and is less applicable in clinical practice than SUVs. We investigated whether SUV could provide adequate quantification of 18F-DCFPyL uptake on PET/CT in a patient cohort with low PCa burden. Methods: In total, 116 patients with PCa undergoing 18F-DCFPyL PET/CT imaging were retrospectively included. All 18F-DCFPyL-avid lesions suspected of being PCa were semiautomatically delineated. SUVpeak was plotted against TBR for the most intense lesion of each patient. The correlation of SUVpeak and TBR was evaluated using linear regression and was stratified for patients undergoing PET/CT for primary staging, patients undergoing restaging at biochemical recurrence, and patients with metastatic castration-resistant PCa. Moreover, the correlation was evaluated as a function of tracer uptake time, prostate-specific antigen level, and PET-positive tumor volume. Results: In total, 436 lesions were delineated (median, 1 per patient; range, 1-66). SUVpeak correlated well with TBR in patients with PCa and a total tumor volume of less than 200 cm3 (R2 = 0.931). The correlation between SUV and TBR was not affected by disease setting, prostate-specific antigen level, or tumor volume. SUVpeak depended less on tracer uptake time than did TBR. Conclusion: For 18F-DCFPyL PET/CT, SUVpeak correlates strongly with TBR. Therefore, it is a valuable simplified, semiquantitative measurement in patients with low-volume PCa (<200 cm3). SUVpeak can therefore be applied in 18F-DCFPyL PET assessment as an imaging biomarker to characterize tumors and to monitor treatment outcomes.
引用
- Bodar YJL, Koene BPF, Jansen BHE, et al. SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden. J Nucl Med. 2021. PMID: 33509971. doi:10.2967/jnumed.120.260232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。